Jounce Therapeutics, Inc. (JNCE)

1.8500 0.0000 (0.00%) At close: 04:00PM EDT

Jounce Therapeutics, Inc.

780 Memorial Drive
Cambridge, MA 02139
United States
857 259 3840
https://jouncetx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 141

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Richard Murray Ph.D.	Pres, CEO & Director	887.4k	N/A	1959
Mr. Hugh M. Cole	Chief Operating Officer	607.44k	N/A	1965
Dr. Elizabeth G. Trehu M.D.	Chief Medical Officer	639.6k	N/A	1960
Dr. James Patrick Allison Ph.D.	Founder	N/A	N/A	N/A
Dr. Thomas F. Gajewski M.D., Ph.D.	Founder	N/A	N/A	N/A
Dr. Robert D. Schreiber Ph.D.	Founder	N/A	N/A	N/A
Dr. Drew Mark Pardoll M.D., Ph.D.	Founder	N/A	N/A	N/A
Dr. Padmanee Sharma M.D., Ph.D.	Founder	N/A	N/A	N/A
Dr. Louis M. Weiner M.D.	Founder	N/A	N/A	1952
Ms. Kimberlee Cobleigh Drapkin CPA, CPA	CFO & Treasurer	N/A	N/A	1968

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Jounce Therapeutics, Inc.’s ISS Governance QualityScore as of March 30, 2023 is 7. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.